Skip to main content
. 2022 Jun 15;12(6):2733–2743.

Figure 3.

Figure 3

H3B-6527 and Lenvatinib effects in the HCC cell line Hep3B in vitro. A. Representative H3B-6527 and Lenvatinib dose response curves for ATP based cell viability assay. B. Representative H3B-6527 and Lenvatinib dose response matrix for ATP based cell viability assay. C. Chalice software was used to calculate excess inhibition over Loewe additivity for H3B-6527 and Lenvatinib dose combination. D. Antitumor effects following H3B-6527 and anti-VEGFR combination treatment in Hep3B HCC cell line xenografts grown in female nude mice. Tumor volume and Body weight measurements following H3B-6527 and DC101 treatment at indicated doses and schedule. Tumor weight measurements on day 21. H3B-6527 was administered by oral gavage, once daily dose (QD). DC101 was administered via intraperitoneal injection (ip) once every three days (Q3D). Data represent the mean ± SEM (N = 8). For TV comparisons, P < 0.05 for all treatment groups when compared to vehicle control on day 21 (Two way ANOVA with Holm Sidak’s post hoc correction); P < 0.05 for the combination treatment group compared to single treatment groups on day 21 (Two way ANOVA with Holm Sidak’s post hoc correction). For Tumor weight comparisons, P < 0.05 for all treatment groups when compared to vehicle control (One-way ANOVA with Tukey’s post hoc correction).